Single-Use Boosts Fill/Finish in Commercial Biomanufacturing
Single-use technologies have become increasingly prevalent in final fill/finish operations for biologics.
The increasing number of biologic drugs in development is driving the need for more efficient and cost-effective manufacturing technologies, including in single-use technologies for final fill/finish. Single-use technologies have become increasingly prevalent in fill/finish as a result of industry demand.
BioPharm Internationalspoke to BJ Hull, vice-president and general manager (Camden), Emergent BioSolutions; Sara Bell, senior marketing manager, Single-use Solutions, MilliporeSigma, a business of Merck KGaA, Darmstadt, Germany; and Claus Feussner, PhD, senior vice-president Vetter Development Service, Vetter Pharma-Fertigung, on the adoption, benefits, and challenges of single-use systems in final fill/finish manufacturing.
Read this article in BioPharm International's Single-Use Systems 2018 eBook.
Article Details
BioPharm International
eBook: BioPharm International Single-Use Systems
Vol. 31
June 2018
Pages: 13–17
Citation
When referring to this article, please cite it as F. Mirasol, “Single-Use Boosts Fill/Finish in Commercial Biomanufacturing,” BioPharm International Single-Use Systems eBook (June 2018).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
